Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
Corrado Pelaia, Claudia Crimi, Santi Nolasco, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1822-1822
Open Access | Times Cited: 23

Showing 23 citing articles:

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 56
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
Corrado Pelaia, Giulia Pelaia, Angelantonio Maglio, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3371-3371
Open Access | Times Cited: 26
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
Raffaele Campisi, Santi Nolasco, Corrado Pelaia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 12, pp. 3953-3953
Open Access | Times Cited: 21
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
Santi Nolasco, Andrea Portacci, Raffaele Campisi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Switching Biological Therapies in Severe Asthma
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 15
Novel Biological Therapies for Severe Asthma Endotypes
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1064-1064
Open Access | Times Cited: 21
Biologics for severe asthma and beyond
Carlo Mümmler, Katrin Milger
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108551-108551
Closed Access | Times Cited: 9
Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
A. Gómez-Bastero Fernández, Juan Francisco Medina Gallardo, Julio Delgado Romero, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 727-735
Open Access | Times Cited: 13
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
Anne-Noëlle Frix, Liam G. Heaney, Barbro Dahlén, et al.
ERJ Open Research (2022) Vol. 8, Iss. 4, pp. 00273-2022
Open Access | Times Cited: 13
Advancing Care in Severe Asthma: The Art of Switching Biologics
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 2, pp. 110-122
Open Access | Times Cited: 2
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Cristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Type 2 severe asthma: pathophysiology and treatment with biologics
Corrado Pelaia, J. Mark Melhorn, Timothy S.C. Hinks, et al.
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 7, pp. 485-498
Closed Access | Times Cited: 1
Choosing the right biologic treatment for individual patients with severe asthma – lessons learnt from Picasso.
Milan Teřl, Zuzana Diamant, Radovan Kosturiak, et al.
Respiratory Medicine (2024) Vol. 234, pp. 107766-107766
Open Access | Times Cited: 1
Experts' Opinion on diagnosis and management of Severe Asthma, an Indian/Low and middle-income countries (LMIC) Perspective.
Raja Dhar, Deepak Talwar, Devasahayam Jesudas Christopher, et al.
Journal of Asthma (2024) Vol. 61, Iss. 10, pp. 1152-1164
Closed Access | Times Cited: 1
Local and Systemic Production of Pro-Inflammatory Eicosanoids Is Inversely Related to Sensitization to Aeroallergens in Patients with Aspirin-Exacerbated Respiratory Disease
Daniel P. Potaczek, Gabriela Trąd, Marek Sanak, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 447-447
Open Access | Times Cited: 6
Asma grave: fisiopatología, diagnóstico y tratamiento
José E. Gereda, Erika De Arruda-Chaves, J I Larco, et al.
Deleted Journal (2024) Vol. 71, Iss. 2, pp. 114-127
Open Access
Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma
Mauli Desai, Adam Haines, John Oppenheimer
Immunology and Allergy Clinics of North America (2024) Vol. 44, Iss. 4, pp. 737-750
Closed Access
Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period
Ai Goto, Sonoko Harada, Hitoshi Sasano, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 1173-1186
Open Access
Biological therapy for severe asthma – Indian perspectives and challenges
Rajesh Venkitakrishnan, Jolsana Augustine, Divya Ramachandran, et al.
Lung India (2023) Vol. 40, Iss. 3, pp. 253-259
Open Access | Times Cited: 1
Switching Biological Therapies in Adults with Severe Asthma: What Are the Dilemmas and Is It Worthwhile?
John D. Politis, Philip G. Bardin
Annals of the American Thoracic Society (2022) Vol. 19, Iss. 12, pp. 1965-1970
Closed Access | Times Cited: 2
Treatment methods for children with severe asthma in and abroad
Akemi Hara
Theoretical and Natural Science (2023) Vol. 6, Iss. 1, pp. 51-56
Open Access
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Mona Al‐Ahmad, Asmaa Ali, Ahmed Maher
Medical Principles and Practice (2023) Vol. 32, Iss. 6, pp. 323-331
Open Access
Page 1

Scroll to top